HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bril, V. Articles by Buchanan, R. A. Search for Related Content PubMed PubMed Citation Articles by Bril, V. Articles by Buchanan, R. A. Social Bookmarking                What's this?

Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy

¹ Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
² Clinical Development, Dainippon Pharmaceutical, Osaka, Japan
³ Dainippon Pharmaceutical U.S.A., Teaneck, New Jersey

Address correspondence and reprint requests to Dr. Vera Bril, EN11-209, Toronto General Hospital, University Health Network, 200 Elizabeth St., Toronto, Ontario, Canada, M5G 2C4. E-mail: vera.bril{at}utoronto.ca

OBJECTIVE—Nerve sorbitol levels have been measured in sural nerve biopsy samples from patients with diabetic sensorimotor polyneuropathy in several studies using different methods and measurement units. In this study, we compared the results of sorbitol assays to determine the required sensitivity of analytical methods for nerve sorbitol measurements.

RESEARCH DESIGN AND METHODS—We performed a literature search using PaperChase for reports of nerve sorbitol in diabetic patients and selected those with nerve conduction studies to delineate the severity of nerve damage.

RESULTS—In patients who had undergone a nerve conduction study, the standardized nerve sorbitol levels were 0.034–0.300 nmol/mg wet nerve.

CONCLUSIONS—Our results showed the level of sensitivity required in laboratory methodology to perform this assay in the target population and aid in the planning of clinical research trials of aldose reductase inhibitor agents.

Abbreviations: DSP, diabetic peripheral sensorimotor polyneuropathy • NCS, nerve conduction study

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. Bril, R. A. Buchanan, and the Ranirestat Study Group* Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy Diabetes Care, January 1, 2006; 29(1): 68 - 72. [Abstract] [Full Text] [PDF]

				V. Bril, R. A. Buchanan, and the AS-3201 Study Group Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy Diabetes Care, October 1, 2004; 27(10): 2369 - 2375. [Abstract] [Full Text] [PDF]